Shares of Humana Inc. (NYSE:HUM - Get Free Report) have been given an average rating of "Hold" by the thirty ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and fourteen have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $403.9130.
A number of equities analysts recently weighed in on the company. Evercore raised Humana from an "in-line" rating to an "outperform" rating and set a $480.00 price target for the company in a report on Wednesday, July 29th. Jefferies Financial Group raised Humana from a "buy" rating to a "buy" rating in a report on Wednesday, May 20th. HSBC cut Humana to a "hold" rating in a research report on Thursday, July 30th. Mizuho upped their target price on Humana from $335.00 to $390.00 and gave the stock an "outperform" rating in a research note on Monday, June 8th. Finally, The Goldman Sachs Group increased their target price on Humana from $158.00 to $195.00 and gave the company a "sell" rating in a research report on Thursday, April 30th.
View Our Latest Report on Humana
Humana Stock Up 0.4%
HUM stock opened at $392.72 on Friday. Humana has a one year low of $163.11 and a one year high of $428.88. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.74 and a current ratio of 1.74. The firm's fifty day moving average is $385.08 and its 200 day moving average is $287.78. The firm has a market cap of $47.16 billion, a PE ratio of 37.15, a P/E/G ratio of 2.23 and a beta of 0.72.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. During the same quarter in the prior year, the firm posted $6.27 earnings per share. The company's revenue was up 26.2% compared to the same quarter last year. On average, research analysts forecast that Humana will post 9.12 EPS for the current year.
Hedge Funds Weigh In On Humana
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Manning & Napier Advisors LLC acquired a new stake in shares of Humana in the second quarter worth approximately $1,412,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Humana by 4.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 250,330 shares of the insurance provider's stock worth $66,207,000 after buying an additional 9,960 shares in the last quarter. Sustainable Insight Capital Management LLC grew its holdings in shares of Humana by 23.7% during the fourth quarter. Sustainable Insight Capital Management LLC now owns 24,757 shares of the insurance provider's stock worth $6,341,000 after buying an additional 4,740 shares in the last quarter. Pzena Investment Management LLC acquired a new stake in shares of Humana in the second quarter valued at about $1,749,014,000. Finally, Swedbank AB lifted its stake in shares of Humana by 6.2% in the fourth quarter. Swedbank AB now owns 111,803 shares of the insurance provider's stock worth $28,636,000 after buying an additional 6,534 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Company Profile
(
Get Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.